Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

Todd Neale

June 06, 2025

News Daily News

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

Todd Neale

April 12, 2024

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

Todd Neale

January 12, 2024

News Daily News

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

Shelley Wood

September 28, 2023

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2021

Caitlin E. Cox

May 03, 2021

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Shelley Wood

January 14, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

A Simple Nudge Moves the Needle on Statin Prescribing

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

TCTMD’s Top 10 Most Popular Stories for April 2021

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

TCTMD’s Top 10 Most Popular Stories for November 2018

TCTMD’s Top 10 Most Popular Stories for August 2018

TCTMD’s Top 10 Most Popular Stories for May 2017

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content